ArticleScience translational medicine2024

An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations.

Michael Westberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.